1 |
New directions in clinical trials for frontotemporal lobar degeneration: Methods and outcome measures.
|
|
|
|
In: Alzheimer's & dementia : the journal of the Alzheimer's Association, vol 16, iss 1 (2020)
|
|
BASE
|
|
Show details
|
|
2 |
Utility of the global CDR® plus NACC FTLD rating and development of scoring rules: Data from the ARTFL/LEFFTDS Consortium.
|
|
|
|
In: Alzheimer's & dementia : the journal of the Alzheimer's Association, vol 16, iss 1 (2020)
|
|
BASE
|
|
Show details
|
|
3 |
New directions in clinical trials for frontotemporal lobar degeneration: Methods and outcome measures.
|
|
|
|
In: Alzheimer's & dementia : the journal of the Alzheimer's Association, vol 16, iss 1 (2020)
|
|
BASE
|
|
Show details
|
|
4 |
Utility of the global CDR® plus NACC FTLD rating and development of scoring rules: Data from the ARTFL/LEFFTDS Consortium.
|
|
|
|
In: Alzheimer's & dementia : the journal of the Alzheimer's Association, vol 16, iss 1 (2020)
|
|
BASE
|
|
Show details
|
|
5 |
Utility of the global CDR® plus NACC FTLD rating and development of scoring rules: Data from the ARTFL/LEFFTDS Consortium
|
|
|
|
In: Alzheimers Dement (2020)
|
|
BASE
|
|
Show details
|
|
|
|